Dr. Michael R. Green
The University of Texas MD Anderson Cancer Center
Departments of Lymphoma/Myeloma and Genomic Medicine
Research in the Green lab is focused on understanding how genetic and epigenetic changes deregulate B-cell differentiation and give rise to B-cell lymphoma and myeloma. We typically employ high-throughput next generation sequencing analysis of primary patient tumors with methodologies such as DNA sequencing (targeted, whole exome, or whole genome), ChIP-seq, ATAC-seq, RNA-seq or single-cell RNA-seq to identify genes, regulatory elements or pathways that are deregulated in B-cell malignancies. We investigate the functional consequences of these alterations using cell line models, transgenic mouse models and patient-derived xenograft models so that we can identify avenues to specifically target associated synthetic dependencies with novel therapeutic approaches. The ultimate goal of our research is to develop novel strategies to take forward into clinical trials, and to improve the outcome of patients with B-cell malignancies.
Some examples of projects that a student may conduct in my laboratory would be (i) to perform high-throughput molecular profiling of a specific subtype of lymphoma to identify disease-defining characteristics that may be amenable to therapeutic targeting, (ii) dissecting the role of a specific gene using CRISPR gene editing in cell lines and transgenic mouse models to understand its function in lymphoma/myeloma genesis or progression, or (iii) pre-clinical testing of novel agents that we have defined as targeting specific molecular alterations using cell line and patient derived xenograft models.